Weekly Report: what happened at GRFS last week (0513-0517)?
Weekly Report · 1d ago
Grifols Chairman Glanzmann Says CFO Alfredo Arroyo To Step Down; Role Of Grifols Chairman Will No Longer Be Executive
Benzinga · 05/14 16:58
Grifols Q1 Net Revenues €1.63 Billion Vs €1.56 Billion YoY; Sees Q1 R&D Negative Net Investment €90.5 Million Vs (€104.7) Million YoY; Currently Working To Improve FCF Guidance In Light Of Several Ongoing Initiatives; To Hold Investor & Analysts Day On Oct 10
Benzinga · 05/14 15:47
UPDATE 2-Grifols shares fall after new Gotham City Research report
Grifols shares fall after Gotham City Research report on Tuesday morning. Short-seller has repeatedly accused drugmaker of manipulating its financial accounts. Spanish drugmaker has previously denied the accusations. The report questioned the accounting treatment of loans involving Grifols and a company tied to the family.
Reuters · 05/14 07:59
Weekly Report: what happened at GRFS last week (0506-0510)?
Weekly Report · 05/13 09:24
Grifols: Why To Watch From The Sidelines
Seeking Alpha · 05/07 09:10
Health Care Sector Update for 05/06/2024: BNTX, GRFS, OM
NASDAQ · 05/06 17:45
Weekly Report: what happened at GRFS last week (0429-0503)?
Weekly Report · 05/06 09:26
Weekly Report: what happened at GRFS last week (0422-0426)?
Weekly Report · 04/29 09:28
Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease
Benzinga · 04/22 12:37
Weekly Report: what happened at GRFS last week (0415-0419)?
Weekly Report · 04/22 09:26
Grifols SA’s Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns
Grifols SA (GRFS) has disclosed a new risk, in the Debt & Financing category. The company engages in transactions with related parties, which raises concerns about potential conflicts of interest. Wall Street has a Strong Buy consensus rating on GRFS stock based on 3 buys.
TipRanks · 04/21 06:00
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Grifols celebrated the 50th anniversary of its flagship site in Clayton, N.C. Today. The company is a leading manufacturer of plasma-derived medicines. Grifols has saved the lives of millions of patients since its inception. The company's production of plasma has saved millions of lives.
Barchart · 04/18 08:30
Grifols reportedly looking to appoint independent directors
Spanish drugmaker Grifols reportedly looking to appoint independent directors. Short-seller Gotham Research accused the company of accounting irregularities in January. The company has been criticized for its accounting practices. Grifol's CEO says appointing independent directors will help improve the company's governance.
Seeking Alpha · 04/15 15:37
Weekly Report: what happened at GRFS last week (0408-0412)?
Weekly Report · 04/15 09:24
ATUS, ATHE and GRFS among pre-market losers
On the Move ATUS, ATHE and GRFS among pre-market losers. Aptevo Therapeutics (APVO) -55% on pricing public offering. Carmax (KMX) -9% after Q4 earnings release. Altice USA, Inc. (ATUS) and Grifols SA (GRFS) in the red.
Seeking Alpha · 04/11 12:16
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Shares of CarMax, Inc. Fell sharply in today’s pre-market trading after the company reported lower-than-expected fourth-quarter earnings. CarMax shares dipped 9.1% to $72.06 in pre- market trading. The Lovesac Company shares fell 13% after reporting worse- than-expected results. The Dow futures fell over 150 points on Thursday.
Benzinga · 04/11 12:03
Analysts Expect 15% Upside For KOMP
NASDAQ · 04/10 14:52
Deals of the day-Mergers and acquisitions
Spanish drug maker Grifols plans to meet its debt payments in 2025. Italy's Italgas has made a preliminary offer worth 4-5 billion euros for 2i Rete Gas. U.S. Rare-earths producer MP Materials says Gina Rinehart's mining firm has taken a stake in the company.
Reuters · 04/10 09:43
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
NASDAQ · 04/09 10:20
Webull provides a variety of real-time GRFS stock news. You can receive the latest news about Grifols S A through multiple platforms. This information may help you make smarter investment decisions.
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.